

Author index

Volume 119 (1996)

- Andersson, A., see Wiklund, O. 119, 99
 Arveiler, D., see Lane, A. 119, 119
 Bara, L., see Lane, A. 119, 119
 Bauer, J., see Lucas, A. 119, 17
 Bétard, C., A.M. Kessling, M. Roy, J. Davignon, Influence of genetic variability in the nondeletion LDL-receptor allele on phenotypic variation in French-Canadian familial hypercholesterolemia heterozygotes sharing a 'null' LDL-receptor gene defect 119, 43
 Bondjers, G., see Wiklund, O. 119, 57
 Boomsma, D.I., see Hoffer, M.J.V. 119, 159
 Borch-Johnsen, K., see Skov Jensen, J. 119, 69
 Bravo, E., G. Ortu, R. Rivabene, M.T. Santini, A. Cantafora, Probucol reduces hepatic cholesterol secretion in hyperlipidemic Yoshida rats 119, 223
 Bräutigam, C., B. Engelmann, D. Reiss, U. Reinhardt, J. Thiery, W.O. Richter, T. Brosche, Plasmalogen phospholipids in plasma lipoproteins of normolipidemic donors and patients with hypercholesterolemia treated by LDL apheresis 119, 77
 Bredie, S.J.H., see Hoffer, M.J.V. 119, 159
 Brennan, C., see Jones, R.J. 119, 151
 Brosche, T., see Bräutigam, C. 119, 77
 Cambien, F., see Lane, A. 119, 119
 Cambou, J.P., see Lane, A. 119, 119
 Camejo, G., see Wiklund, O. 119, 57
 Cantafora, A., see Bravo, E. 119, 223
 Cantin, B., see Lamarche, B. 119, 235
 Chagpar, A., see Lucas, A. 119, 17
 Chung, T.K.H., see Haines, C.J. 119, 215
 Collins, P.B., see Jones, R.J. 119, 151
 Dagenais, G.R., see Lamarche, B. 119, 235
 Dai, E., see Lucas, A. 119, 17
 Darley-Usmar, V., see O'Leary, V.J. 119, 169
 Davignon, J., see Bétard, C. 119, 43
 de Knijff, P., see Hoffer, M.J.V. 119, 159
 Demacker, P.N.M., see Hoffer, M.J.V. 119, 159
 Després, J.-P., see Lamarche, B. 119, 235
 Dobmeyer, J., J. Lohrmann, G. Feussner, Prevalence and association of atherosclerosis at three different arterial sites in patients with type III hyperlipoproteinemia 119, 89
 Engelmann, B., see Bräutigam, C. 119, 77
 Evans, A., see Lane, A. 119, 119
 Fager, G., see Wiklund, O. 119, 99
 Feldt-Rasmussen, B., see Skov Jensen, J. 119, 69
 Feussner, G., see Dobmeyer, J. 119, 89
 Firth, J.C., see Naoumova, R.P. 119, 203
 Fleetwood, G., see O'Leary, V.J. 119, 169
 Frants, R.R., see Hoffer, M.J.V. 119, 159
 Fuller, C.J., S.M. Grundy, E.P. Norkus, I. Jialal, Effect of ascorbate supplementation on low density lipoprotein oxidation in smokers 119, 139
 Garbutt, M., see Lucas, A. 119, 17
 Gnasso, A., C. Irace, P.L. Mattioli, A. Pujia, Carotid intima-media thickness and coronary heart disease risk factors 119, 7
 Green, F., see Lane, A. 119, 119
 Grundy, S.M., see Fuller, C.J. 119, 139
 Hakamata, H., see Sakai, M. 119, 191
 Havekes, L.M., see Hoffer, M.J.V. 119, 159
 He, Y., W.C.P. Kwan, U.P. Steinbrecher, Effects of oxidized low density lipoprotein on endothelin secretion by cultured endothelial cells and macrophages 119, 107
 Horiuchi, S., see Sakai, M. 119, 191
 Hoffer, M.J.V., S.J.H. Bredie, D.I. Boomsma, P.W.A. Reymer, J.J.P. Kastelein, P. de Knijff, P.N.M. Demacker, A.F.H. Stalenhoef, L.M. Havekes, R.R. Frants, The lipoprotein lipase (Asn291 → Ser) mutation is associated with elevated lipid levels in families with familial combined hyperlipidaemia 119, 159
 Hultberg, B., see Wiklund, O. 119, 99
 Humphries, S., see Lane, A. 119, 119
 Irace, C., see Gnasso, A. 119, 7

- Jensen, G., see Skov Jensen, J. 119, 69
- Haines, C.J., T.K.H. Chung, J.R.L. Masarei, B. Tomlinson, J.T.F. Lau, An examination of the effect of combined cyclical hormone replacement therapy on lipoprotein(a) and other lipoproteins 119, 215
- Jialal, I., see Fuller, C.J. 119, 139
- Jiang, X.Y., see Lucas, A. 119, 17
- Johnson, A.H., see Jones, R.J. 119, 151
- Jokela, H., see Nikkilä, M. 119, 181
- Jones, R.J., D. Owens, C. Brennan, P.B. Collins, A.H. Johnson, G.H. Tomkin, Increased esterification of cholesterol and transfer of cholesteryl ester to apo B-containing lipoproteins in Type 2 diabetes: relationship to serum lipoproteins A-I and A-II 119, 151
- Kang, S.-S., P.W.K. Wong, Genetic and nongenetic factors for moderate hyperhomocyst(e)inemia 119, 135
- Kappagoda, C.T., see Skepper, J.N. 119, 247
- Kastelein, J.J.P., see Hoffer, M.J.V. 119, 159
- Kessling, A.M., see Bétard, C. 119, 43
- Kobori, S., see Sakai, M. 119, 191
- Koivula, T., see Nikkilä, M. 119, 181
- Kwan, W.C.P., see He, Y. 119, 107
- Laippala, P., see Nikkilä, M. 119, 181
- Lamarche, B., J.-P. Després, S. Moorjani, B. Cantin, G.R. Dagenais, P.-J. Lupien, Triglycerides and HDL-cholesterol as risk factors for ischemic heart disease. Results from the Québec cardiovascular study 119, 235
- Lane, A., F. Green, P.Y. Scarabin, V. Nicaud, L. Bara, S. Humphries, A. Evans, G. Luc, J.P. Cambou, D. Arveiler, F. Cambien, Factor VII Arg/Gln₃₅₃ polymorphism determines factor VII coagulant activity in patients with myocardial infarction (MI) and control subjects in Belfast and in France but is not a strong indicator of MI risk in the ECTM study 119, 119
- Lau, J.T.F., see Haines, C.J. 119, 215
- Lehtimäki, T., see Nikkilä, M. 119, 181
- Lehtomäki, E., see Nikkilä, M. 119, 181
- Liu, L.-y., see Lucas, A. 119, 17
- Lohrmann, J., see Dobmeyer, J. 119, 89
- Luc, G., see Lane, A. 119, 119
- Lucas, A., W. Yue, X.Y. Jiang, L.-y. Liu, W.-d. Yan, J. Bauer, W. Schneider, J. Tulip, A. Chagpar, Lundstam, U., see Wiklund, O. 119, 99
- Lupien, P.-J., see Lamarche, B. 119, 235
- Marais, A.D., see Naoumova, R.P. 119, 203
- Masarei, J.R.L., see Haines, C.J. 119, 215
- Masson, P., see Wiklund, O. 119, 99
- Mattioli, P.L., see Gnasso, A. 119, 7
- Miyazaki, A., see Sakai, M. 119, 191
- Montague, P., see Lucas, A. 119, 17
- Moorjani, S., see Lamarche, B. 119, 235
- Morikawa, W., see Sakai, M. 119, 191
- Mountney, J., see Naoumova, R.P. 119, 203
- Naoumova, R.P., A.D. Marais, J. Mountney, J.C. Firth, N.B. Rendell, G.W. Taylor, G.R. Thompson, Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia 119, 203
- Nicaud, V., see Lane, A. 119, 119
- Nikkilä, M., T. Pitkälä, T. Koivula, T. Solakivi, T. Lehtimäki, P. Laippala, H. Jokela, E. Lehtomäki, K. Seppä, Norkus, E.P., see Fuller, C.J. 119, 139
- Nourooz-Zadeh, J., see Wolff, S.P. 119, 261
- O'Leary, V.J., L. Tilling, G. Fleetwood, D. Stone, V. Darley-Usmar, The resistance of low density lipoprotein to oxidation promoted by copper and its use as an index of antioxidant therapy 119, 169
- Ortu, G., see Bravo, E. 119, 223
- Owens, D., see Jones, R.J. 119, 151
- Perk, M., see Lucas, A. 119, 17
- Pitkälä, T., see Nikkilä, M. 119, 181
- Puddey, I.B., Review article Low serum cholesterol and the risk of cerebral haemorrhage 119, 1
- Pujia, A., see Gnasso, A. 119, 7
- Radosavljevic, M., see Lucas, A. 119, 17
- Reinhardt, U., see Bräutigam, C. 119, 77
- Reiss, D., see Bräutigam, C. 119, 77
- Rendell, N.B., see Naoumova, R.P. 119, 203
- Reymer, P.W.A., see Hoffer, M.J.V. 119, 159
- Richter, W.O., see Bräutigam, C. 119, 77
- Rivabene, R., see Bravo, E. 119, 223
- Roy, M., see Bétard, C. 119, 43
- Sakai, M., A. Miyazaki, H. Hakamata, Y. Suginoara, Y.-I. Sakamoto, W. Morikawa, S. Kobori, M. Shichiri, S. Horiuchi, Reconstituted high density lipoprotein reduces the capacity of oxidatively modified low density lipoprotein to accumulate cholesteryl esters in mouse peritoneal macrophages 119, 191
- Sakamoto, Y.-I., see Sakai, M. 119, 191
- Santini, M.T., see Bravo, E. 119, 223
- Scarabin, P.Y., see Lane, A. 119, 119
- Schneider, W., see Lucas, A. 119, 17
- Seppä, K., see Nikkilä, M. 119, 181
- Shichiri, M., see Sakai, M. 119, 191
- Sillanauke, P., see Nikkilä, M. 119, 181
- Skepper, J.N., C.T. Kappagoda, The effect of isradipine administration on existing fatty streaks in the cholesterol-fed rabbit: A morphometric study 119, 247
- Skov Jensen, J., K. Borch-Johnsen, G. Jensen, B. Feldt-Rasmussen, Insulin sensitivity in clinically healthy individuals with microalbuminuria 119, 69
- Solakivi, T., see Nikkilä, M. 119, 181
- Stalenhoef, A.F.H., see Hoffer, M.J.V. 119, 159
- Steinbrecher, U.P., see He, Y. 119, 107
- Stone, D., see O'Leary, V.J. 119, 169
- Suginoara, Y., see Sakai, M. 119, 191
- Taylor, G.W., see Naoumova, R.P. 119, 203

- Thiery, J., see Bräutigam, C. 119, 77
 Thompson, G.R., see Naoumova, R.P. 119, 203
 Tilling, L., see O'Leary, V.J. 119, 169
 Tomkin, G.H., see Jones, R.J. 119, 151
 Tomlinson, B., see Haines, C.J. 119, 215
 Tulip, J., see Lucas, A. 119, 17
 Wiklund, O., G. Bondjers, I. Wright, G. Camejo, Insoluble complex formation between LDL and arterial proteoglycans in relation to serum lipid levels and effects of lipid lowering drugs 119, 57
 Wiklund, O., G. Fager, A. Andersson, U. Lundstam, P. Masson, B. Hultberg, *N*-acetylcysteine treatment lowers plasma homocysteine but not serum lipoprotein(a) levels 119, 99
 Wolff, S.P., J. Nourooz-Zadeh, Hypothesis: UK consumption of dietary lipid hydroperoxides — a possible contributory factor to atherosclerosis 119, 261
 Wong, P.W.K., see Kang, S.-S. 119, 135
 Wright, I., see Wiklund, O. 119, 57
 Yan, W.-d., see Lucas, A. 119, 17
 Yue, W., see Lucas, A. 119, 17



Subject index

Volume 119 (1996)

- Alcohol 119, 235
Alpha tocopherol 119, 77
Apolipoprotein A-II 119, 151
Apolipoprotein E 119, 89, 181
Apoprotein A-I 119, 151
Ascorbate 119, 139
Atherosclerosis 119, 7, 17, 57, 89, 107, 169
Atherosclerotic vascular disease 119, 69
Atorvastatin 119, 203
Avian model 119, 17
- Bile 119, 223
Blood pressure 119, 69
Body weight 119, 69
- Cerebral haemorrhage 119, 1
Cholesterol 119, 223, 235, 247
Cholesterol 119, 159
Cholesterol biosynthesis 119, 203
Cholesteryl ester transfer protein 119, 151
Coronary artery disease 119, 181
Coronary heart disease 119, 215
Cysteine 119, 99
- Dietary lipid 119, 261
Digitonin 119, 247
Discoidal HDL 119, 191
Dysbetalipoproteinemia 119, 89
- Echo-Doppler 119, 7
ECTIM 119, 119
Endothelial cells 119, 107
Endothelin 119, 107
- Factor VII Arg/Gln₃₅₃ polymorphism 119, 119
Factor VII coagulant activity 119, 119
Familial combined hyperlipidaemia 119, 159
Familial hypercholesterolaemia 119, 203
Familial hypercholesterolemia 119, 43
Fatty streak 119, 247
Foam cell formation 119, 191
- Free radicals 119, 139
- Genetic defects 119, 135
- Haplotype 119, 43
HDL 119, 77
HDL-C 119, 235
Homocysteine 119, 99
Homocystinuria 119, 135
Hydroperoxides 119, 261
Hyperhomocyst(e)inemia 119, 135
Hyperlipidemia 119, 57, 223
- Inheritance 119, 135
Insulin sensitivity 119, 69
Isradipine 119, 247
- LDL 119, 139
LDL oxidation 119, 169
LDL receptor 119, 43
LDL size 119, 181
Lecithin:cholesterol acyltransferase 119, 151
Lipid lowering therapy 119, 1
Lipids 119, 69
Lipoprotein 119, 223
Lipoprotein(a) 119, 99, 215
Lipoprotein lipase 119, 159
Lipoproteins 119, 57, 215
Liver 119, 223
Low density lipoprotein 119, 181
LPL(Asn291 → Ser) mutation 119, 159
- Macrophages 119, 107
Macrophage scavenger receptor(s) 119, 191
Menopause 119, 215
Microalbuminuria 119, 69
MI risk factors 119, 119
Morphometry 119, 247
- N-acetylcysteine 119, 99

Oxidation 119, 139
Oxidized LDL 119, 107, 191

Phospholipid transfer 119, 191
Plasma mevalonic acid 119, 203
Plasmenylcholine 119, 77
Plasmenylethanolamine 119, 77
Polyunsaturated fatty acids 119, 77
Pravastatin 119, 203
Probucol 119, 169
Proteoglycans 119, 57

Rats 119, 223
Red blood cell membranes 119, 77
Regression 119, 247
Restenosis 119, 17
Risk Factors 119, 235

Serum cholesterol 119, 1
Simvastatin 119, 203
Smoking 119, 139

Thrombosis risk factors 119, 119
Triglycerides 119, 159, 235
Type 2 diabetes 119, 151
Type III hyperlipoproteinemia 119, 89

Ultrasound 119, 7

Vascular disease 119, 135

Watanabe rabbits 119, 169